NASDAQ:MGNXMacroGenics Stock Price, Forecast & News

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MGNX shares have increased by 342.1% and is now trading at $28.69. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for MacroGenics.

MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.10. The biopharmaceutical company earned $13.68 million during the quarter, compared to analysts' expectations of $7.43 million. MacroGenics had a negative return on equity of 62.43% and a negative net margin of 222.14%. View MacroGenics' earnings history.

13 brokers have issued 12 month price objectives for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they expect MacroGenics' stock price to reach $29.33 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View analysts' price targets for MacroGenics.

News coverage about MGNX stock has trended neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MacroGenics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about MacroGenics.

MacroGenics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,720,000 shares, an increase of 9.0% from the June 15th total of 4,330,000 shares. Based on an average trading volume of 3,180,000 shares, the short-interest ratio is currently 1.5 days. Approximately 10.6% of the company's stock are sold short. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), Zai Lab (ZLAB), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), Myokardia (MYOK), Biohaven Pharmaceutical (BHVN), Blueprint Medicines (BPMC) and Nektar Therapeutics (NKTR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Bausch Health Companies (BHC), Epizyme (EPZM), Incyte (INCY), Karyopharm Therapeutics (KPTI) and Nektar Therapeutics (NKTR).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.02%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics.

MGNX stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. View insider buying and selling activity for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $28.69.

MacroGenics has a market capitalization of $1.41 billion and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe.

The official website for MacroGenics is www.macrogenics.com.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.